

***Bacteroides fragilis*, Strain CL03T12C07**

Catalog No. HM-714

Product Description:

Bacteroides fragilis (*B. fragilis*), strain CL03T12C07 was isolated from healthy adult human feces in Massachusetts, USA.

Lot: 70013560^{1,2}

Manufacturing Date: 22MAR2018

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis Cellular morphology Colony morphology ³ Motility VITEK® MS (MALDI-TOF)	Gram-negative rods Report results Report results <i>B. fragilis</i>	Gram-negative rods Circular, low convex, entire, smooth and gray (Figure 1) Non-motile <i>B. fragilis</i> (99.9%)
Antibiotic Susceptibility Profile Sensititre™ System ^{4,5} Amoxicillin/Clavulanic Acid Ampicillin/Sulbactam Cefotetan Cefoxitin Chloramphenicol Clindamycin Imipenem Meropenem Metronidazole Mezlocillin Piperacillin Piperacillin/Tazobactam Tetracycline	Report results Report results Report results Report results Report results Report results Report results Report results Report results Report results Report results Report results Report results	Sensitive (≤ 0.5 µg/mL) Sensitive (≤ 0.5 µg/mL) Sensitive (≤ 4 µg/mL) Sensitive (8 µg/mL) Sensitive (4 µg/mL) Sensitive (0.5 µg/mL) Sensitive (≤ 0.12 µg/mL) Sensitive (≤ 0.5 µg/mL) Sensitive (4 µg/mL) 8 µg/mL Sensitive (≤ 4 µg/mL) Sensitive (≤ 0.25 µg/mL) > 8 µg/mL ⁶
Genotypic Analysis Sequencing of 16S ribosomal RNA gene (~ 1410 base pairs)	≥ 99% sequence identity to <i>B. fragilis</i> , strain CL03T12C07 (GenBank: AGXL01000027.1)	99.7% sequence identity to <i>B. fragilis</i> , strain CL03T12C07 (GenBank: AGXL01000027.1)
Purity (post-freeze) Anaerobic growth ⁷ Aerobic growth ⁸	Consistent with expected colony morphology No growth	Consistent with expected colony morphology No growth
Viability (post-freeze)³	Growth	Growth

¹Quality control of HMP material is only performed to demonstrate that the material distributed by BEI Resources is identical to the deposited material. It should not be considered a complete characterization of the deposited organism.

²*B. fragilis*, strain CL03T12C07 was deposited by Laurie E. Comstock, Ph.D., Associate Microbiologist, Department of Medicine, Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. HM-714 lot 70013560 was produced by the inoculation of BEI Resources HMS-714 lot 62323796 into Modified Reinforced Clostridial broth and incubated for 3 days at 37°C in an anaerobic atmosphere (< 5% O₂; Remel™ Pack-Anaero™). Broth inoculum was added to Tryptic Soy agar with 5% defibrinated sheep blood kolles and grown for 3 days at 37°C in an anaerobic atmosphere to produce this lot.

³2 days at 37°C in an anaerobic atmosphere on Tryptic Soy agar with 5% defibrinated sheep blood

⁴Sensititre™ System Anaerobe MIC Plate, Thermo Scientific™, catalog number ANO2B

⁵Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

⁶Susceptibility results for this antibiotic cannot be determined since the maximum concentration of antibiotic tested is 8 µg/mL, which is interpreted as intermediate.

⁷Purity of this lot was assessed for 7 days at 37°C in an anaerobic atmosphere on Tryptic Soy agar with 5% defibrinated sheep blood.

⁸Purity of this lot was assessed for 7 days at 37°C in an aerobic atmosphere with 5% CO₂ on Tryptic Soy agar with 5% defibrinated sheep blood.

Figure 1: Colony Morphology



/Heather Couch/
Heather Couch

Program Manager or designee, ATCC Federal Solutions

14 NOV 2019

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

